Daily Bulletin

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically

- Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma

MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular...

Read more: PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant...

Business News

Tips from Organisational Change Management Experts for Leading Successful Transitions

Corporate evolution has accelerated dramatically in today's volatile business environment, requiring leaders to develop sophisticated approaches to managing workforce transitions across technologica...

Daily Bulletin - avatar Daily Bulletin

Cross-Continental Collaboration: Nutifood and Viplus Dairy to Create Australian- Standard Premium Dairy Brand

Vietnam’s Nutifood has officially entered a strategic partnership with ViPlus Dairy, a heritage-rich dairy manufacturer with over 130 years of experience in Gippsland, Australia, to establish an int...

Daily Bulletin - avatar Daily Bulletin

Beyond the Marker: How Modern Whiteboards Drive Team Collaboration

In an age where flexibility and innovation define competitive advantage, the humble whiteboard has undergone a transformation. From static office fixture to dynamic collaboration hub, modern whiteboar...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals